

May 5, 2022

**Dr. Scott Morrow,** Health Officer **Marc Meulman,** Director

Public Health, Policy & Planning 225 37th Avenue San Mateo, CA 94403 smchealth.org

#### **CLINICAL PEARL**

Sensitivity of home COVID-19 rapid antigen tests

According to a recent study, the sensitivity of home rapid antigen COVID-19 tests peaks 4 days after symptom onset, suggesting that a negative antigen test should be followed by a second test in 1 or 2 days. The study studied test sensitivity in 225 adults and children from 107 households who tested positive for COVID-19 in San Diego County, California, and metropolitan Denver from January to May 2021. Participants used antigen tests for 15 days and had at least one same-day reverse-transcription (RT) PCR test and viral culture. A total of 3,044 antigen tests and 642 PCR tests were performed. Average participant age was 29 years, 52% were female, and 91% had COVID-19 symptoms.

Antigen tests were less sensitive than PCR, but more sensitive than viral culture. During the first few days of illness, antigen test sensitivity was 50% (95% confidence interval [CI], 45% to 55%). Overall antigen test sensitivity was 64% (95% CI, 56% to 70%) and 84% (95% CI, 75% to 90%) compared to PCR and viral culture, respectively.

Sensitivity of the antigen tests peaked at 77% (95% CI, 69% to 83%) 4 days after symptom onset and was 81% to 85% on a second test 1 or 2 days later. PCR positivity peaked at 95% 3 days after illness onset, while viral cultures peaked at 64% on day 2. Six days after symptom onset, antigen test positivity was 61% (95% CI, 53% to 68%), falling to less than 20% by day 11.

Of note, the study authors pointed out that antigen test performance may differ in vaccinated and unvaccinated people and among infections with different SARS-CoV-2 variants.

#### PUBLIC HEALTH UPDATES

- CDC Health Advisory: <u>Updated Information on Availability and Use of Treatments for Outpatients with Mild</u> to Moderate COVID-19 Who are at Increased Risk for Severe Outcomes of COVID-19
- FDA Announces Tentative Advisory Committee Meeting Schedule Regarding COVID- 19 Vaccines
- FDA Approves First COVID-19 Treatment for Young Children
- WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator

## **GUIDANCE/GUIDELINES**

- CDC Interim Clinical Considerations for COVID-19 Vaccines
- NIH COVID-19 Treatment Guidelines Update: What's New in the Guidelines

#### **RESOURCES**

- IDSA
  - COVID-19 Podcast: <u>The Latest on Long COVID</u>
  - Vaccine Education Roundtable Series: <u>The Future of Minoritized Communities in the COVID-19</u>
    Pandemic, Part 1 Data and the Impact of COVID-19
- Kaiser Family Foundation COVID-19 mortality preventable by vaccines
- Center for Infectious Disease Research and Policy (CIDRAP) Osterholm Update:
  - o Episode 100: You Can't Stop the Wind
  - o Episode 101: Class in Complicated Times





**Dr. Scott Morrow,** Health Officer **Marc Meulman,** Director

Public Health, Policy & Planning 225 37th Avenue San Mateo, CA 94403 smchealth.org

### ACADEMIC/RESEARCH PAPERS

#### Nature

- Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness
- o <u>Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19</u> in adults aged over 60 years
- o <u>Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine</u>
- Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost
- Risk factors for severe COVID-19 differ by age for hospitalized adults

#### bioRxiv

 P681 mutations within the polybasic motif of spike dictate fusogenicity and syncytia formation of SARS CoV-2 variants

#### medRxiv

- Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity
- o <u>Determinants of SARS-CoV-2 anti-spike antibody levels following BNT162b2 vaccination: cross-</u> sectional analysis of 6,000 SIREN study participants
- Continued Emergence and Evolution of Omicron in South Africa: New BA.4 and BA.5 lineages

#### The Lancet

- o <u>Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study</u>
- o Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design
- o <u>The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads</u>
- Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study
- Sustainability of surveillance systems for SARS-CoV-2
- o An online breathing and wellbeing programme (ENO Breathe) for people with persistent symptoms following COVID-19: a parallel-group, single-blind, randomised controlled trial
- Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort
- Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries
- Effect of lockdown on mental health in Australia: evidence from a natural experiment analysing a longitudinal probability sample survey

## • New England Journal of Medicine

o Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

## JAMA

- Assessment of T-cell Reactivity to the SARS-CoV-2 Omicron Variant by Immunized Individuals
- o Association of SARS-CoV-2 Infection During Pregnancy With Maternal and Perinatal Outcomes
- SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents
- Comparison of Home Antigen Testing With RT-PCR and Viral Culture During the Course of SARS-CoV-2 Infection
- Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19 - The HITCH Randomized Clinical Trial



**Dr. Scott Morrow,** Health Officer **Marc Meulman,** Director

Public Health, Policy & Planning 225 37th Avenue San Mateo, CA 94403 smchealth.org

- Association of Short-term Air Pollution Exposure With SARS-CoV-2 Infection Among Young Adults in Sweden
- o COVID-19 Vaccination and Estimated Public Health Impact in California
- o <u>Association of Large Financial Incentives With COVID-19 Vaccination Uptake Among Employees of a</u> Large Private Company
- Stress-Related Disorders of Family Members of Patients Admitted to the Intensive Care Unit With COVID-19

### • Emerging Infectious Diseases

- o Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant–Infected Vaccinees
- o <u>Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough</u> Complications, Israel
- Disparities in First Dose COVID-19 Vaccination Coverage among Children 5–11 Years of Age, United States
- Estimating Relative Abundance of 2 SARS-CoV-2 Variants through Wastewater Surveillance at 2 Large
  Metropolitan Sites, United States
- Detection of SARS-CoV-2 B.1.351 (Beta) Variant through Wastewater Surveillance before Case Detection in a Community, Oregon, USA
- Increased COVID-19 Severity among Pregnant Patients Infected with SARS-CoV-2 Delta Variant, France
- o <u>Epidemiologic and Genomic Analysis of SARS-CoV-2 Delta Variant Superspreading Event in Nightclub,</u> the Netherlands, June 2021
- o High-Dose Convalescent Plasma for Treatment of Severe COVID-19
- Severe Multisystem Inflammatory Symptoms in 2 Adults after Short Interval between COVID-19 and Subsequent Vaccination
- o Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination
- o Guillain-Barré Syndrome Associated with COVID-19 Vaccination
- o SARS-CoV-2 Seroprevalence after Third Wave of Infections, South Africa
- o SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia
- SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan
- o <u>Mathematical Modeling for Removing Border Entry and Quarantine Requirements for COVID-19, Vanuatu</u>
- Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan

#### PLOS

- COVID-19 mortality in the United States: It's been two Americas from the start
- Clinical Infectious Diseases
  - Reductions in Antibiotic Prescribing in Australia During the SARS-CoV-2 Pandemic: National Prescribing
    Data
- Vaccine
  - o Readability of COVID-19 Vaccine Information for the General Public

### **MMWR**

- Provisional COVID-19 Age-Adjusted Death Rates, by Race and Ethnicity United States, 2020–2021
- Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies United States, September 2021—February 2022
- Hospitalizations of Children Aged 5–11 Years with Laboratory-Confirmed COVID-19 COVID-NET, 14 States, March 2020–February 2022





**Dr. Scott Morrow,** Health Officer **Marc Meulman,** Director

Public Health, Policy & Planning 225 37th Avenue San Mateo, CA 94403 smchealth.org

## HOT OFF THE (LAY) PRESS

- New York Times
  - Loss of Pandemic Aid Stresses Hospitals That Treat the Uninsured
  - o <u>Vaccines for Young Children</u>
  - o Vaccines for young children are being delayed by incomplete data, a top F.D.A. official suggests.
  - Moderna said it had asked the F.D.A. to authorize its coronavirus vaccine for children under 6, making it the first manufacturer to do so.
  - o Should You Still Wear a Mask? Experts weigh in on where, and when, you can safely take one off.
  - Where You Still Have to Wear a Mask in California
- The Hill
  - Moderna expects 'large amounts' of omicron booster available by fall
- Politico
  - Waiting for a Covid vaccine for your under-5 kid? It may take a bit longer.
- CNBC
  - o At least a dozen U.S. universities reinstate mask mandates as Covid cases rise
- AP News
  - o Boston officials recommend wearing masks indoors again
  - Biden admin to promote availability of COVID antiviral pill
  - Racial split on COVID-19 endures as restrictions ease in US
  - o Most people in US want masks for travelers: AP-NORC poll
- The Washington Post
  - o Virus mutations aren't slowing down. New omicron subvariant proves it.
  - o Covid deaths no longer overwhelmingly among the unvaccinated as toll on elderly grows
- Bloomberg
  - U.S. Seeks Data on Post-Paxlovid Rebound
- Scientific American
  - Nose Spray Vaccines Could Quash COVID Virus Variants
- EurekaAlert!
  - Six in ten people with COVID-19 still have a least one symptom a year later, long Covid study reveals
  - Long COVID associated with different clinical trajectories and characteristics depending on severity of initial SARS-CoV-2 infection
  - Long Covid fatigue eased by four-week occupational therapy program, Irish study finds
  - Pregnant women with COVID-19 face greater risk of hospitalisation and ICU admission, strengthening case for vaccination
  - o Patients hospitalized with COVID-19 were three times as likely to die than those with seasonal influenza
  - o Longer interval between COVID-19 vaccines generates up to nine times as many antibodies
  - Omicron infection just 20 days after Delta the shortest known gap between infections
- European Commission Press Releases
  - o COVID-19: Commission calls on Member States to step up preparedness for the next pandemic phase
- Moderna News
  - MODERNA FILES FOR AUTHORIZATION OF ITS COVID-19 VACCINE IN YOUNG CHILDREN SIX MONTHS TO UNDER SIX YEARS OF AGE



**Dr. Scott Morrow,** Health Officer **Marc Meulman,** Director

Public Health, Policy & Planning 225 37th Avenue San Mateo, CA 94403 smchealth.org

- Pfizer Press Releases
  - o <u>Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine</u> Booster Dose in Children 5 Through 11 Years of Age
  - Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use
- Los Angeles Times
  - o Here we go again: California coronavirus cases rising. Is a new wave coming soon?
  - o CDC restates recommendation for masks on planes, trains despite court ruling
- San Francisco Chronicle
  - Bay Area COVID cases and hospitalizations rise again as new infections swell in April
  - o Why aren't more Californians getting second COVID booster shots? It's complicated
  - o As COVID cases 'swell' in the Bay Area, this time it's on you to weigh the risks

### **EPIDEMIOLOGY UPDATES**

- CDC COVID-19 Community Levels
- CDC COVID Data Tracker
  - Variant Proportions
  - Wastewater Surveillance
  - o COVID-19 Vaccinations in the United States
- Johns Hopkins COVID-19 in the USA daily summary of key data on COVID-19 in the U.S.
- American Academy of Pediatrics Children and COVID-19: State Level Data Report new data!
- California COVID-19 by the numbers are available on the <u>CDPH Website</u> and the <u>NYT Map and Table</u> (includes data by county)
  - o California COVID-19 Statewide Update as of May 5, 2022
- San Mateo County COVID-19 Dashboard
- Santa Clara County COVID-19 Dashboard

#### ADDITIONAL COVID-19 RESOURCES

- San Mateo County COVID-19 Guidance and Resources for Clinicians and Facilities COVID-19 Digests
- Covid-WEB (Wastewater Epidemiology for the Bay Area)
- Palo Alto Online tracking the coronavirus in San Mateo and Santa Clara counties
- California COVID-19 Data and Tools
- CDPH COVID-19 Assessment and Modeling Tool
- California Department of Corrections and Rehabilitations Population COVID-19 Tracking Dashboards
- CDC Interactive Serology Dashboard for Commercial Laboratory Surveys
- HHS Coronavirus Data Hub
- COVID-19 Nursing Home Data

